Acceleron to Present at the Oppenheimer 19th Annual Health Care Conference

CAMBRIDGE, Mass. – November 3, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the Oppenheimer 19th Annual Health Care Conference on Tuesday November 4, 2008 at 8:00 AM (EST) at the Waldorf-Astoria Hotel in New York City.

About Acceleron

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the Growth and Differentiation Factor (GDF) family of proteins. ACE-011, a novel bone forming compound, is the Company’s lead compound and is being developed to reverse bone loss in diseases such as cancer-related bone loss in a strategic alliance with the multinational biopharmaceutical company Celgene Corporation. ACE-031, a novel muscle building compound, is being developed to increase muscle mass and strength. In addition, the company is advancing through preclinical development product candidates that control angiogenesis and inhibit fat accumulation. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal Good Manufacturing Practice (GMP) manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Bessemer Ventures, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For more information, visit www.acceleronpharma.com.

CONTACT:
Acceleron Pharma:
Steven Ertel, 617-649-9234
Vice President, Corporate Development

Paul Kidwell (Media)
Suda Communications LLC, tel: 617-296-3854

BACK TO PRESS RELEASES